L-Glutamine 用于 Crohn's Disease
CSmall RCTs show glutamine (0.5 g/kg/day) improves intestinal permeability and morphology in Crohn's patients. Evidence limited by small sample sizes.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dl\u002Dglutamine\u0026condition\u003Dibd\u002Dcrohns\u002Ddisease';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
C
结论
Small RCTs show glutamine (0.5 g/kg/day) improves intestinal permeability and morphology in Crohn's patients. Evidence limited by small sample sizes.
Key Study Findings
Other
Multiomics reveals microbial metabolites as key actors in intestinal fibrosis in Crohn's disease.
Dose: None
vs: None
Outcome: Gut microbiota composition
效果: None
None
研究人群: Crohn's disease patients
Other
Multi-Omics Reveals the Effects of Cannabidiol on Gut Microbiota and Metabolic Phenotypes.
Dose: None
vs: None
Outcome: Cholesterol levels
效果: None
None
研究人群: Mouse model
Controlled Clinical Trial
Washed microbiota transplantation for Crohn's disease: A metagenomic, metatranscriptomic, and metabolomic-based study.
Dose: Washed microbiota transplantation (WMT)
vs: Pre-treatment baseline
Outcome: Clinical remission and multi-omics changes
效果: None
None
研究人群: Patients with Crohn's disease
In Vitro
Constitutively active autophagy in macrophages dampens inflammation through metabolic and post-transcriptional regulation of cytokine production.
Dose: Beclin1 constitutive activation (genetic)
vs: Wild-type mice
Outcome: Cytokine production in macrophage activation
效果: None
None
研究人群: Beclin1 variant mice + AIEC infection
Observational Study
n=262
Gut Microbiome-Generated Phenylacetylglutamine from Dietary Protein is Associated with Crohn's Disease and Exacerbates Colitis in …
Dose: Phenylacetylglutamine (PAGln, measured)
vs: Healthy controls (n=126)
Outcome: PAGln association with CD and colitis
效果: None
None
研究人群: New-onset treatment-naive CD (n=136) + controls
Observational Study
COMPLEMENTARY AND ALTERNATIVE MEDICINE USE IN BRAZILIAN PATIENTS WITH INFLAMMATORY BOWEL DISEASE.
Dose: None
vs: None
Outcome: CAM use patterns in IBD patients
效果: None
None
研究人群: Brazilian IBD patients
Key Statistics
3
研究数量
200
受试者
↑
Positive
C
等级
Referenced Papers
Multiomics reveals microbial metabolites as key actors in intestinal fibrosis in Crohn's disease.
Other
EMBO molecular medicine
2024
13 次引用
Cannabis and cannabinoid …
2024
10 次引用
World journal of …
2024
Cell reports
2023
27 次引用
Journal of Crohn's …
2023
24 次引用
JCI insight
2022
24 次引用
Sheng wu gong …
2022
4 次引用
COMPLEMENTARY AND ALTERNATIVE MEDICINE USE IN BRAZILIAN PATIENTS WITH INFLAMMATORY BOWEL DISEASE.
Other
Arquivos de gastroenterologia
2022
4 次引用
Effects of glutamine supplementation on inflammatory bowel disease: A systematic review of clinical trials.
Systematic Review
Clinical nutrition ESPEN
2021
39 次引用
Gastroenterology
2019
118 次引用
Journal of cellular …
2019
23 次引用
The Cochrane database …
2018
425 次引用
Gastroenterology clinics of …
2018
67 次引用
Clinical medicine insights. …
2018
15 次引用
Nutrition in clinical …
2018
10 次引用
Current opinion in …
2017
37 次引用
JPEN. Journal of …
2017
24 次引用
World journal of …
2017
21 次引用
The AAPS journal
2017
Glutamine for induction of remission in Crohn's disease.
Systematic Review
The Cochrane database …
2016
37 次引用
Scandinavian journal of …
2014
56 次引用
Digestive diseases and …
2012
81 次引用
Frontline gastroenterology
2012
20 次引用
Plasma citrulline concentration as a marker for disease activity in patients with Crohn's disease.
Other
Journal of clinical …
2012
13 次引用
Pediatrics in review
2012
International journal of …
2011
12 次引用
Inflammatory bowel diseases
2010
89 次引用
Nutricion hospitalaria
2010
Nutrition in clinical …
2009
36 次引用
The Journal of …
2008
89 次引用
Molecular nutrition & …
2008
26 次引用
The Cochrane database …
2007
192 次引用
Digestive diseases and …
2006
73 次引用
Immunonutrition.
Review
Current opinion in …
2005
22 次引用
JPEN. Journal of …
2005
19 次引用
Clinical nutrition (Edinburgh, …
2004
18 次引用
Medycyna wieku rozwojowego
2004
1 次引用
Annali italiani di …
2004
Alimentary pharmacology & …
2003
179 次引用
Nutricion hospitalaria
2003
Revista do Hospital …
2002
39 次引用
Scandinavian journal of …
2002
28 次引用
Enteral feeding.
Other
Current opinion in …
2002
1 次引用
Enteral feeding.
Review
Current opinion in …
2002
Enteral nutritional therapy for inducing remission of Crohn's disease.
Systematic Review
The Cochrane database …
2001
149 次引用
Journal of pediatric …
2000
187 次引用
Current opinion in …
2000
21 次引用
JPEN. Journal of …
2000
18 次引用
JPEN. Journal of …
1999
129 次引用
Diseases of the …
1998
26 次引用
Zeitschrift fur Gastroenterologie
1998
18 次引用
FASEB journal : …
1997
170 次引用
Schweizerische medizinische Wochenschrift. …
1996
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
常用剂量
- general:
- 5-15 g/day
- ibsdsupport:
- 5 g three times daily (15 g/day total)
- postexercisegut:
- 0.25-0.9 g/kg before intense exercise
- gutbarriersupport:
- 0.5 g/kg/day (approximately 30-40 g/day for adults)
上限： Generally well-tolerated up to 0.5 g/kg/day; caution above 40 g/day
研究中使用的剂量
| 剂量 | 持续时间 | 效果 | N |
|---|---|---|---|
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| Washed microbiota transplantation (WMT) | -- | Positive | -- |
| Beclin1 constitutive activation (genetic) | -- | Positive | -- |
| Phenylacetylglutamine (PAGln, measured) | -- | Negative | 262 |
| None | -- | Mixed | -- |
| None | -- | Negative | -- |
| None | -- | Mixed | -- |
最佳服用时间： Between meals or before exercise; divide doses throughout the day
Safety & Side Effects
已报告的副作用
- ⚠ Mild gastrointestinal discomfort at high doses
- ⚠ Headache
- ⚠ Dizziness at very high doses
- ⚠ Potential glutamate excitotoxicity concerns in neurological conditions (theoretical)
已知相互作用
- ● Lactulose (glutamine may reduce the efficacy of lactulose for hepatic encephalopathy)
- ● Anti-seizure medications (glutamine converts to glutamate; theoretical concern)
- ● Chemotherapy agents (glutamine may protect cancer cells; discuss with oncologist)
可耐受最高摄入量： Generally well-tolerated up to 0.5 g/kg/day; caution above 40 g/day
在开始服用任何补充剂之前，请务必咨询您的医疗保健提供者。
Frequently Asked Questions
Does L-Glutamine help with Crohn's Disease?
Based on 3 studies with 200 participants, there is limited but promising evidence that L-Glutamine may support Crohn's Disease management. Our evidence grade is C (Some Evidence).
How much L-Glutamine should I take for Crohn's Disease?
Studies have used various dosages. A commonly studied range is 5-15 g/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of L-Glutamine?
Reported side effects may include Mild gastrointestinal discomfort at high doses, Headache, Dizziness at very high doses, Potential glutamate excitotoxicity concerns in neurological conditions (theoretical). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for L-Glutamine and Crohn's Disease?
We rate the evidence as Grade C (Some Evidence). This rating is based on 3 peer-reviewed studies with 200 total participants. The overall direction of effect is positive.
Related Evidence
其他成分用于 Crohn's Disease
L-Glutamine 用于其他健康状况
FDA 免责声明: 这些声明未经美国食品药品监督管理局（FDA）评估。本网站上的产品和信息无意用于诊断、治疗、治愈或预防任何疾病。所展示的证据等级基于我们对已发表的同行评审研究的分析，不构成医疗建议。在开始任何补充剂方案之前，请务必咨询您的医疗保健提供者。